Asianet Newsable on MSN

FATE stock jumps 6% as FDA greenlights moving cell therapy to clinical trials

The clearance allows the company to begin an early-stage basket trial in multiple autoimmune diseases later this year.

Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)

Fate Therapeutics pivots to autoimmune CAR T-cell therapies, with FT819 advancing toward a registrational lupus nephritis ...
Insider Monkey

Is FATE A Good Stock To Buy According To Hedge Funds?

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of ...
Nasdaq

Can Fate Therapeutics Continue Its Rally After A 16% Move In 5 Days?

The stock price of Fate Therapeutics (FATE) has seen a solid 16% rise over the last five trading days, while it’s up 13% over the last ten trading days, and we believe the rally may continue in the ...
Nasdaq

Can Fate Therapeutics Stock Rebound After A 20% Drop?

[Updated: 3/30/2021] Can FATE Stock Rebound? The stock price of Fate Therapeutics (NASDAQ:FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer (NK) ...